For instance, the effective time frame for treating NSCLC with first-generation epidermal growth factor receptor (EGFR) TKIs does not exceed one year.6 In addition, a small proportion of tumor cells are primarily resistant to TKIs. Here, EGFR is linked to neoplasm.